lobbying_activities: 2069566

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2069566	09631fcb-958e-4d90-b197-8c7d8a6e69e0	Q4	NOVO NORDISK INC.	284790	NOVO NORDISK INC.	2017	fourth_quarter	PHA	Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; H.R. 4710, the 340B Protecting Access for the Underserved and Safety-Net Entities Act (340 PAUSE Act)and other issues related to 340B program	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE		290000	0	0	2018-01-18T21:09:00.640000-05:00